Department of Clinical Dentistry, Centre for Clinical Dental Research, University of Bergen, Bergen, Norway.
Norwegian Center for Stem Cell Research, Department of Immunology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Sci Rep. 2019 Nov 5;9(1):16031. doi: 10.1038/s41598-019-52442-9.
Therapeutic potential of human bone marrow stromal/stem cells (hBMSC) must be developed using well defined xenogenic-free conditions. hBMSC were isolated from healthy donors (n = 3) using different isolation and expansion methods. Donor I was isolated and expanded by either bone marrow directly seeded and cells expanded in 10% AB human serum (AB) +5 ng/ml fibroblast growth factor-2 (FGF2) [Direct(AB + FGF)] or Ammonium-Chloride-Potassium Lysing Buffer was used before the cells were expanded in 10% AB +5 ng/ml FGF-2 [ACK(AB + FGF)] or Lymphoprep density gradient medium was used before the cells were expanded in 10% AB +5 ng/ml FGF2 [Lympho(AB + FGF] or bone marrow directly seeded and cells expanded in 10% pooled platelet lysate plasma (PL) + heparin (2 I/U/mL) [Direct(PL)]. Groups for donors II and III were: Direct(AB + FGF) or 10% AB +10 ng/ml FGF2 [Direct(AB + FGF)] or Direct(PL). HBMSCs were assessed for viability, multi-potency, osteogenic, inflammatory response and replicative senescence in vitro after 1 and 3 weeks. Pre-selected culture conditions, Direct(AB + FGF) or Direct(PL), were seeded on biphasic calcium phosphate granules and subcutaneously implanted in NOD/SCID mice. After 1 and 11 weeks, explants were analysed for inflammatory and osteogenic response at gene level and histologically. To identify implanted human cells, in situ hybridisation was performed. hBMSC from all conditions showed in vitro multi-lineage potency. hBMSCs expanded in PL expressed stemness markers in vitro at significantly higher levels. Generally, cells expanded in AB + FGF2 conditions expressed higher osteogenic markers after 1 week both in vitro and in vivo. After 11 weeks in vivo, Direct(AB + FGF) formed mature ectopic bone, compared to immature mineralised tissues formed by Direct(PL) implants. Mouse responses showed a significant upregulation of IL-1α and IL-1β expression in Direct(PL). After 1 week, human cells were observed in both groups and after 11 weeks in Direct(AB + FGF) only. To conclude, results showed a significant effect of the isolation methods and demonstrated a relatively consistent pattern of efficacy from all donors. A tendency of hBMSC expanded in PL to retain a more stem-like phenotype elucidates their delayed differentiation and different inflammatory expressions.
人骨髓基质/干细胞(hBMSC)的治疗潜力必须在明确的无异种生物条件下开发。使用不同的分离和扩增方法从健康供体(n=3)中分离和扩增 hBMSC。供体 I 是通过直接接种骨髓并在 10%AB 人血清(AB)+5ng/ml 成纤维细胞生长因子-2(FGF2)中扩增[直接(AB+FGF)]或使用氯化铵-钾裂解缓冲液在 10%AB+5ng/ml FGF-2 中扩增[ACK(AB+FGF)]或淋巴细胞分离液密度梯度介质在 10%AB+5ng/ml FGF2 中扩增[淋巴细胞(AB+FGF)]或直接接种骨髓并在 10%富含血小板的血浆(PL)+肝素(2I/U/mL)中扩增[直接(PL)]。供体 II 和 III 的分组为:直接(AB+FGF)或 10%AB+10ng/ml FGF2[直接(AB+FGF)]或直接(PL)。在第 1 周和第 3 周后,通过体外评估 HBMSC 的活力、多能性、成骨、炎症反应和复制衰老。在经过预筛选的培养条件下,直接(AB+FGF)或直接(PL)接种于双相磷酸钙颗粒并皮下植入 NOD/SCID 小鼠。在第 1 周和第 11 周,通过基因水平和组织学分析研究植入物的炎症和成骨反应。为了鉴定植入的人细胞,进行原位杂交。所有条件下的 hBMSC 在体外均表现出多能性。在 PL 中扩增的 hBMSC 在体外以显著更高的水平表达干性标志物。一般来说,在第 1 周,在体外和体内,在 AB+FGF2 条件下扩增的细胞表达更高的成骨标志物。在体内第 11 周,与直接(PL)植入物形成的未成熟矿化组织相比,直接(AB+FGF)形成成熟异位骨。小鼠反应显示直接(PL)中 IL-1α 和 IL-1β 表达显著上调。第 1 周观察到两组均有人类细胞,第 11 周仅在直接(AB+FGF)组观察到。总之,结果表明分离方法有显著影响,并从所有供体中证明了相对一致的疗效模式。PL 中扩增的 hBMSC 保持更类似干细胞表型的趋势表明其分化延迟和不同的炎症表达。